Viking Therapeutics

Alnylam Pharmaceuticals

Gilead Sciences

Exact Sciences

Sarepta Therapeutics

Incyte

United Therapeutics

Vertex Pharmaceuticals

AbbVie

Insmed

SPDR S&P Biotech ETF

XBI tracks an equal-weighted index of US biotechnology stocks.

A smart beta exchange traded fund, the SPDR S&P Biotech ETF (XBI) debuted on 01/31/2006, and offers broad exposure to the Health Care ETFs category of the market.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

SPDR® S&P Biotech ETF is a well-diversified, low-cost ETF that can be an excellent tool to capitalize on the potential of the biotech stock sector. XBI's performance should be compared with the Russell 2000, not the S&P 500, due to its heavy focus on small- and mid-cap stocks. I believe that economic conditions are favorable for growth in the biotechnology sector, despite the recent spike in over 20-year Treasury bond yields.

XBI: Biotech ETF Is A Must Have

Exelixis

Amicus Therapeutics

Merck

Teva Pharmaceutical

The small cap biotech sector is trading close to the same levels that it was five years ago. Straight equity holdings have threaded water in this space over the past half decade. However, given the lucrative option premiums available against many names in this area, a covered call strategy has worked quite successfully for my portfolio on a consistent basis.

3 Attractive Biotechs With Recent Positives

Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund launched on 01/31/2006.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Dynavax Technologies

GlaxoSmithKline

Intellia Therapeutics

Small-cap biotech stocks have struggled over the past five years, but lower interest rates may boost sentiment and M&A activity, benefiting the sector. One way I have kept my biotech portfolio churning out profits is by embracing using covered call orders to establish positions in small-cap biotech names. Many of these have become consistent profitable “rinse, wash and repeat” trades over the years.

3 'Repeatable' Biotech Trades

iShares Nasdaq Biotechnology ETF

As a new regime and phase begin for the market and economy, after the FED cut interest rates by a surprising 50bps last Wednesday, several new opportunities and sector bull and bear markets might begin.

Biotech Boom Ahead? Key Stocks and ETFs to Watch Now

Biotechnology equities have underperformed since late 2020, but recent acquisitions and drug approvals suggest a potential industry revaluation. SPDR S&P Biotech ETF (XBI) offers broad exposure to the biotech sector, with equal weighting reducing susceptibility to individual stock movements. XBI shows strong support around $96 and $90, with the potential to break resistance at $102.50, especially if the Federal Reserve cuts rates.

XBI Is Breaking Out And Likely To Outperform In The Near Term (Technical Analysis)

Thanks to the prospect of lower interest rates, shares of biotech companies have doubled the gains of the broad market over the past few months.

Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue.

Stock valuations in the pharmaceutical industry are becoming more attractive for potential mergers due to declining IPO prices. Aging population and prevalence of chronic diseases are driving favorable prospects for the drug industry.

Biopharmaceutical Stocks: The Next Phase Of The Rally Appears To Be Underway

iShares Core U.S. Aggregate Bond ETF

YieldMax COIN Option Income Strategy ETF

Calamos S&P 500 Structured Alt Protection ETF-August

Invesco DB Agriculture Fund

Eaton Vance Floating-Rate ETF

VanEck Junior Gold Miners ETF

iShares iBoxx High Yield Corporate Bond ETF

iShares iBoxx $ Investment Grade Corporate Bond ETF

iShares MSCI Global Gold Miners ETF

Amplify Junior Silver Miners ETF

 SPDR Blackstone Senior Loan ETF

iShares 20+ Year Treasury Bond ETF

Yieldmax Tsla Option Income Etf

United States Natural Gas Fund LP

Global X Uranium ETF

Hello! Bonds seemed more appealing to ETF investors than ever before in July, based on flow data from State Street. This week's ETF Wrap looks at what's driving investors' appetite for fixed income lately, and where their money flowed within fixed income.

Bond ETFs attract record flows in July as investors position for Fed rate cuts

Biotech indexes lagged broader market indexes in the first half of 2024, and trade at the same level as in early 2022. Biotech valuations are closely tied to the Fed's interest rate policy and are highly correlated to the 10-year yield. Inflation is likely to trend lower, and, along with rising unemployment, should persuade the Fed to cut rates this year in September.

Biotech Stocks 2024 Second Half Outlook - Buy Biotechs

Amgen

Bristol-Myers

Ionis Pharma

Mergers and acquisitions are on pace for a solid year. Small-cap biotech and tech look interesting.

M&A Is Back. 4 Stocks That Could Be Targets.

One of our favorite parts of rolling into a new month at Schaeffer's is digging into seasonality and historic trends of stocks, sectors, and exchange traded funds (ETFs).

Outperforming ETF Could Keep Rallying in June

Altimmune

Structure Therapeutics Inc

Undervalued biotech stocks can offer some of the most explosive opportunities. That is, if you can spot the right one at the right time.

The 3 Most Undervalued Biotech Stocks to Buy in June 2024

Principal Healthcare Innovators Index ETF

Fidelity MSCI Health Care ETF

First Trust Health Care AlphaDEX Fund

Amplify Treatments Testing & Advancements ETF

Global X Health Care Covered Call & Growth ETF

SPDR S&P Insurance ETF

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Invesco DWA Healthcare Momentum ETF

Invesco S&P 500 Equal Weight Health Care ETF

SPDR Portfolio S&P 500 Growth ETF

SPDR Portfolio S&P 500 Value ETF

Amplify Weight Loss Drug & Treatment ETF

Vanguard Health Care ETF

SPDR S&P Health Care Equipment ETF

SPDR S&P Health Care Services ETF

Health Care Select Sector SPDR Fund

SPDR S&P Pharmaceuticals ETF

Sometimes it feels like it's Nvidia's world and we all just live in it. Why bother with anything else?

Finding Opportunity in Unloved Healthcare ETFs

Innovation has been a hallmark of biotechnology for decades and, despite some of the hardest sledding in many years, 2024 could be a bounce-back year for biotech stocks. The sector has suffered in this cycle.

Why the Rest of 2024 Could Be Good for Investing in Biotech Stocks

Biotech indexes, represented by IBB and XBI, have been facing pressure since March and trading at valuations seen in April 2020. The key factor influencing biotech valuations, discussed below, is expected to become more favorable in the second half as rate-cut uncertainty diminishes. While biotechs have significantly lagged behind the broader market, there is reason to be optimistic once inflation-related volatility subsides. IBB and XBI present good vehicles for biotech exposure.

For Biotech Stocks To Move Higher, This Must Move Lower

ARK 21Shares Bitcoin ETF

ARK Genomic Revolution Multi-Sector ETF

Aberdeen Standard Bloomberg All Commodity Strategy K-1 Free ETF

Abrdn Bloomberg Industrial Metals Strategy K-1 Free ETF

ProShares Bitcoin Strategy ETF

Fidelity Wise Origin Bitcoin Fund

VanEck Bitcoin Trust

iShares Bitcoin Trust

iShares U.S. Pharmaceuticals ETF

Global X Lithium & Battery Tech ETF

AdvisorShares Pure US Cannabis ETF

SPDR S&P 500 ETF Trust

Hello! This week's ETF Wrap digs into the slump in ETF flows in April and investor positioning around commodities as inflation worries persist.

Why investor appetite for commodity funds picked up despite ETF flows broadly seeing ‘pretty big drop' in April

The biotech sector has experienced significant volatility but has returned around the same as the risk-free return from the 10-Year Treasury over the past year. There are two key items that will determine the direction of small and midcap biotech stocks in the months and quarters ahead. These are highlighted in the paragraphs below about SPDR® S&P Biotech ETF.

XBI: The 2 Things Biotech Needs To Move Higher

SPDR S&P Biotech ETF offers a buying opportunity after a recent decline and trades close to the 200-day moving average. XBI has a strong long-term track record, providing generous total returns for shareholders. The biotech sector is seeing increased levels of merger and acquisition deals, indicating potential undervaluation in biotech stocks.

XBI: 3 Reasons To Buy The Pullback And Hold This Biotech ETF Forever

Eli Lilly

Nuvectis Pharma

Schrodinger 

What has been the top-performing stock so far of 2024? If you had said server installer Super Micro Computer (NASDAQ: SMCI ), that would be a great answer.

5 Healthcare Stocks to Buy for 2024

JPMorgan Equity Premium Income ETF

SPDR Portfolio High Yield Bond ETF

The SPDR Biotech ETF makes investing in the complicated biotechnology sector easy. The SPDR Portfolio High Yield Bond ETF generates a treasure trove of income from junk bonds.

3 Top ETFs I Plan to Buy in April

Madrigal Pharmaceuticals

After a strong resurgence in the back half of 2023 and continued momentum into the first quarter of 2024, biotech stocks are back in vogue. “Hawkish” Federal Reserve Policy, a brutal bear market in 2022, and investor preference for big tech stocks have meant underperformance for biotech stocks.

2 Top Biotech Buyout Candidates

Pyxis Oncology

One of the best dip-buying opportunities in biotech stocks to buy was in Viking Therapeutics (NASDAQ: VKTX ). After hitting a high of $99.41, VKTX dipped back to about $60.30.

News for SPDR S&P Biotech ETF ETF (XBI)